Key result
GCH1 X haplotype is linked to reduced BH4, higher vascular superoxide, and impaired vasorelaxation in CAD.
Why the study?
Does the GCH1 X haplotype affect BH4 bioavailability, vascular superoxide production, and endothelial function in patients with CAD undergoing CABG?
Observational (n=347)
Does the GCH1 X haplotype affect BH4 bioavailability, vascular superoxide production, and endothelial function in patients with CAD undergoing CABG?
Genetic variation in the GCH1 gene (X haplotype) significantly impairs endogenous BH4 availability, leading to endothelial dysfunction and increased oxidative stress in patients with coronary artery disease.
Objectives This study sought to determine the effects of endogenous tetrahydrobiopterin (BH4) bioavailability on endothelial nitric oxide synthase (eNOS) coupling, nitric oxide (NO) bioavailability, and vascular superoxide production in patients with coronary artery disease (CAD). Background GTP-cyclohydrolase I, encoded by the GCH1 gene, is the rate-limiting enzyme in the biosynthesis of BH4, an eNOS cofactor important for maintaining enzymatic coupling. We examined the associations between haplotypes of the GCH1 gene, GCH1 expression and biopterin levels, and the effects on endothelial function and vascular superoxide production. Methods Blood samples and segments of internal mammary arteries and saphenous veins were obtained from patients with CAD undergoing coronary artery bypass grafting (n = 347). The GCH1 haplotypes were defined by 3 polymorphisms: rs8007267G<A, rs3783641A<T, and rs10483639C<G (X haplotype: A, T, G; O haplotype: any other combination). Vascular superoxide (± the eNOS inhibitor NG-nitro-L-arginine methyl ester [L-NAME]) was measured by lucigenin-enhanced chemiluminescence, whereas the vasorelaxations of saphenous veins to acetylcholine were evaluated ex vivo. Results Haplotype frequencies were OO 70.6%, XO 27.4%, and XX 2.0%. The X haplotype was associated with significantly lower vascular GCH1 messenger ribonucleic acid expression and substantial reductions in both plasma and vascular BH4 levels. In X haplotype carriers both vascular superoxide and L-NAME–inhibitable superoxide were significantly increased, and were associated with reduced vasorelaxations to acetylcholine. Conclusions GCH1 gene expression, modulated by a particular GCH1 haplotype, is a major determinant of BH4 bioavailability both in plasma and in the vascular wall in patients with CAD. Genetic variation in GCH1 underlies important differences in endogenous BH4 availability and is a determinant of eNOS coupling, vascular redox state, and endothelial function in human vascular disease.
No takes yet. Share an insight, caveat, or question.
Antoniades et al. (2008) conducted an observational in Coronary artery disease (n=347). GCH1 X haplotype vs. GCH1 O haplotype was evaluated on Vascular GCH1 mRNA expression, BH4 levels, vascular superoxide, and vasorelaxations to acetylcholine. The GCH1 X haplotype was associated with significantly lower vascular GCH1 expression, reduced BH4 levels, increased vascular superoxide, and reduced vasorelaxation in patients with CAD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: